Stifel lowered the firm’s price target on RxSight to $65 from $70 and keeps a Buy rating on the shares. Shares should “snap back from an inexplicably-pronounced intraquarter sell-off” following “a strong beat-and-raise,” the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST: